TY - JOUR
T1 - Management of Postmenopausal Osteoporosis
T2 - ACOG Clinical Practice Guideline No. 2
AU - Pinkerton, Jo Ann V.
AU - Chelmow, David
AU - Witkop, Catherine T.
N1 - Publisher Copyright:
© 2022 by the American College of Obstetricians and Gynecologists.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - PURPOSE:To provide updated evidence-based recommendations for the treatment of postmenopausal osteoporosis.TARGET POPULATION:Postmenopausal patients with primary osteoporosis.METHODS:This guideline was developed using an a priori protocol in conjunction with a writing team consisting of two specialists in obstetrics and gynecology appointed by the ACOG Committee on Clinical Practice Guidelines-Gynecology and one external subject matter expert. ACOG medical librarians completed a comprehensive literature search for primary literature within Cochrane Library, Cochrane Collaboration Registry of Controlled Trials, EMBASE, PubMed, and MEDLINE. Studies that moved forward to the full-text screening stage were assessed by two authors from the writing team based on standardized inclusion and exclusion criteria. Included studies underwent quality assessment, and a modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) evidence-to-decision framework was applied to interpret and translate the evidence into recommendation statements.RECOMMENDATIONS:This Clinical Practice Guideline includes updated recommendations on who should receive osteoporosis pharmacotherapy, the benefits and risks of available pharmacotherapy options, treatment monitoring and follow-up, and the role of calcium and vitamin D in the management of postmenopausal osteoporosis. Recommendations are classified by strength and evidence quality. Ungraded Good Practice Points are included to provide guidance when a formal recommendation could not be made because of inadequate or nonexistent evidence.
AB - PURPOSE:To provide updated evidence-based recommendations for the treatment of postmenopausal osteoporosis.TARGET POPULATION:Postmenopausal patients with primary osteoporosis.METHODS:This guideline was developed using an a priori protocol in conjunction with a writing team consisting of two specialists in obstetrics and gynecology appointed by the ACOG Committee on Clinical Practice Guidelines-Gynecology and one external subject matter expert. ACOG medical librarians completed a comprehensive literature search for primary literature within Cochrane Library, Cochrane Collaboration Registry of Controlled Trials, EMBASE, PubMed, and MEDLINE. Studies that moved forward to the full-text screening stage were assessed by two authors from the writing team based on standardized inclusion and exclusion criteria. Included studies underwent quality assessment, and a modified GRADE (Grading of Recommendations Assessment, Development, and Evaluation) evidence-to-decision framework was applied to interpret and translate the evidence into recommendation statements.RECOMMENDATIONS:This Clinical Practice Guideline includes updated recommendations on who should receive osteoporosis pharmacotherapy, the benefits and risks of available pharmacotherapy options, treatment monitoring and follow-up, and the role of calcium and vitamin D in the management of postmenopausal osteoporosis. Recommendations are classified by strength and evidence quality. Ungraded Good Practice Points are included to provide guidance when a formal recommendation could not be made because of inadequate or nonexistent evidence.
UR - http://www.scopus.com/inward/record.url?scp=85130862702&partnerID=8YFLogxK
U2 - 10.1097/AOG.0000000000004730
DO - 10.1097/AOG.0000000000004730
M3 - Article
C2 - 35594133
AN - SCOPUS:85130862702
SN - 0029-7844
VL - 139
SP - 698
EP - 717
JO - Obstetrics and gynecology
JF - Obstetrics and gynecology
IS - 4
ER -